Trial reportPloS one2022
Evaluation of the efficacy of Lactobacillus-containing feminine hygiene products on vaginal microbiome and genitourinary symptoms in pre- and postmenopausal women: A pilot randomized controlled trial.
Trial report in PloS one, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 27 citations in OpenAlex.
- Associations of vaginal microbiota with the onset, severity, and type of symptoms of genitourinary syndrome of menopause in women.Frontiers in cellular and infection microbiology · 2024Trial
- The Urogenital Microbiome-Metabolic Interface in Postmenopausal Recurrent Urinary Tract Infection: Estrogen Deficiency, Diabetes, Obesity, and Microbial Reservoirs.Journal of clinical medicine · 2026Review
- The urinary microbiome, overactive bladder and bladder pain syndrome/interstitial cystitis - mechanisms, diagnostics and therapeutic opportunities.Nature reviews. Urology · 2026Review
- The Vaginal Microbiome and Recurrent and Chronic Urinary Tract Infection.International urogynecology journal · 2026Review
- Multi-site microbiota crosstalk in the postmenopausal: from dysbiosis mechanisms to precision interventions.Frontiers in microbiology · 2026Review
- Role of Vaginal Microbiota and OralBioengineering (Basel, Switzerland) · 2025Article
- The gut immune axis in ulcerative colitis: insights from microbiome research.Molecular biology reports · 2025Review
- Probiotics: A New Approach for the Prevention and Treatment of Cervical Cancer.Probiotics and antimicrobial proteins · 2025Review
- Beyond hormones: 3PM approach to vaginal microbiota dynamics in postmenopausal women.The EPMA journal · 2025Review
- The Role of Urinary Microbiome Analysis in the Diagnostic Approach and Management of Urinary Incontinence: A Systematic Review.Life (Basel, Switzerland) · 2025Review
- Isolation of New Strains of Lactic Acid Bacteria from the Vaginal Microbiome of Postmenopausal Women and their Probiotic Characteristics.Current microbiology · 2025Article
- Association between vaginal microecological alterations and high-risk human papillomavirus infection: a cross-sectional study.Frontiers in cellular and infection microbiology · 2025Article
- Untargeted Metabolomics Analysis of Vaginal Secretion Reveals Potential Pathogenesis of Atrophic Vaginitis.Current pharmaceutical design · 2025Article
- Insomnia and Female Reproductive Diseases: A Cross-Sectional and Mendelian Randomization Study.International journal of women's health · 2025Article
- Article
- Crosstalk between the Resident Microbiota and the Immune Cells Regulates Female Genital Tract Health.Life (Basel, Switzerland) · 2023Review
- Differences in the Urinary Microbiome of Patients with Overactive Bladder Syndrome with and without Detrusor Overactivity on Urodynamic Measurements.Life (Basel, Switzerland) · 2023Article
- Menopausal Changes in the Microbiome-A Review Focused on the Genitourinary Microbiome.Diagnostics (Basel, Switzerland) · 2023Review
- Postbiotics in the medical field under the perspective of the ISAPP definition: scientific, regulatory, and marketing considerations.Frontiers in pharmacology · 2023Article
- The vulvar microbiome in lichen sclerosus and high-grade intraepithelial lesions.Frontiers in microbiology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As estrogen level decreases with aging, the vaginal mucosa gets thinner, and collagen amount decreases. In addition, the population of Lactobacillus in the vagina declines, increasing the risk of atrophic vaginitis, bacterial vaginosis, and genitourinary symptoms in the postmenopausal women. In this study, we evaluated the effects of Lactobacillus-containing feminine hygiene products on vaginal microbiome and genitourinary symptoms in pre- and postmenopausal women. This was a pilot randomized controlled trial in 35 premenopausal and 35 postmenopausal healthy women. For 4 weeks, treatment 1 group (14 premenopausal and 16 postmenopausal women) used the Lactobacillus-containing feminine soap and cream, and treatment 2 group (15 premenopausal and 14 postmenopausal women) used Lactobacillus-containing feminine gel in addition to soap and cream. The remaining 6 premenopausal and 5 postmenopausal women served as controls without using any products. We then compared the changes in the vaginal microbiota, genitourinary symptoms, and other related biomarkers after completion of treatment. Vaginal pH and pathogenic flora were reduced in both treatment groups compared to control group, which was more significant in the treatment 2 group of postmenopausal women. Genitourinary symptoms significantly improved in 60% of premenopausal women in treatment 1 group and 81.3% of postmenopausal women in treatment 2 group, compared to control group (0%, p = 0.043 and p<0.01 respectively). Overactive bladder symptom scores were significantly improved after using the products in eleven out of twelve postmenopausal women suspected of having overactive bladder. The use of Lactobacillus-containing feminine products was associated with improved vaginal ecosystem and urogenital health compared to control group, especially in those women using feminine gel.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.